Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s258, 2023. DOI: 10.25251/skin.7.supp.258. Disponível em: https://skin.dermsquared.com/skin/article/view/2428. Acesso em: 22 may. 2026.